This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Friday morning at SXSW , Niall Firth , the Executive Editor of the Newsroom at the Massachusetts Institute of Technology (MIT), reviewed MITs annual list of 10 breakthrough technologies for 2025. The Top Ten Breakthrough Technologies for 2025 Here are the ten technologies that made this years list: Vera C.
by Dennis Crouch The Supreme Court's 2024-2025 patent docket has a growing number of cases awaiting consideration. Two cases raise what I see as core substantive patent law issues outside of eligibility: Converter Manufacturing questions the court's long-standing approach to prior art enablement.
As part of this change, the Coverage Gap Discount Program (CGDP), a program that has existed since 2011, will sunset on December 31, 2024, and be replaced by the Medicare Part D Manufacturer Discount Program (the “Discount Program”). CMS will send the final manufacturer invoice for discount liabilities accrued by then on April 30, 2028.
29, 2025) (precedential); and Regeneron Pharms., 29, 2025) (nonprecedential). The cases pit Regeneron against foreign manufacturers, including Samsung Bioepis (SB) and Formycon AG, who had obtained FDA approval for their biosimilar products under the Biologics Price Competition and Innovation Act (BPCIA). Regeneron Pharms.,
21) – Whether a manufacturer can file a petition for review in a circuit where it does not reside or have its principal place of business as long as it is joined by a seller of its products that is located within that circuit. Share The Supreme Court will hear an important First Amendment case on Jan. 13 and continues until Jan. Paxton (Jan.
As I wrote in an October 2024 post, this case raised fundamental questions about whether composition of matter claims could ever be considered abstract ideas simply because they included functional limitations or defined the composition through its properties rather than manufacturing steps. US Synthetic Corp. Int'l Trade Comm'n , No.
14, 2025) (Lourie, J.). This latest ruling stands in contrast to the court's January 2025 decisions upholding preliminary injunctions against Samsung Bioepis and Formycon, effectively blocking their biosimilar launches. Regeneron Pharms., Mylan Pharms. 2024-2351 (Fed.
The American Conference Institutes 12th Annual Legal, Regulatory, and Compliance Forum on Cosmetics & Personal Care is scheduled to take place from March 27-28, 2025, at the New York City Bar Association, New York, NY.
Within the Notification, FDA references a General Correspondence Letter (GCL) sent on February 26, 2025. FDA has recently issued an updated Notifications on Data Integrity Medical Devices.
Gaulkin Drug manufacturers wont be receiving their first invoices for Medicare Part B and Part D inflation rebates until later this year, but rebates have been accruing since first quarter 2023 for Part B rebates and October 2022 for Part D rebates. The webinar will explore the legal and operational considerations for drug manufacturers.
Nitrosamines are impurities that can form during drug manufacturing and are considered potentially potent carcinogens. For example, depending on the manufacturing process for a specific human drug, the use of some specific solvents, reagents, and catalysts may trigger the formation of these possible carcinogens.
The American Conference Institutes popular FDA Boot Camp now in its 43rd iteration is scheduled to take place from March 19-20, 2025, at the NY Bar Association in New York, NY. The conference is billed as the premier event to provide folks with a roadmap to navigate the difficult terrain of FDA regulatory law. And it is exactly that!
Selling web users' personal data is big business — with a projected worth of $400 billion by 2025. In industries as diverse as health insurance and automobile manufacturing.
The Centers for Disease Control and Prevention is reporting sharp year-over-year increases in its estimates of indicators such as flu-related hospitalizations for the 2024-2025 cycle. billion; and Aerospace manufacturer Triumph Group Inc. Flu season has hit the United States with a vengeance this year. a price of approximately $6.25
gun manufacturers. Estados Unidos Mexicanos , alleges the manufacturers aided and abetted the illegal sales of guns to traffickers for cartels in Mexico. gun manufacturers and one gun distributor. A decision is expected before the end of the term in June/July 2025. The suit, Smith & Wesson Brands v.
by Dennis Crouch The Federal Circuit has affirmed the PTAB finding of obviousness in an inter partes review (IPR) challenge to an integrated circuit manufacturing patent, even while disagreeing with the Board's claim construction. HD Silicon Solutions LLC v. Microchip Technology Inc. , 2023-1397 (Fed.
Trusting suppliers is still fundamental to any drug or device manufacturer. A 2025 study reported by Radical Compliance found that while senior management often believes in the robustness of their ethical culture, employees at other levels do not. Department of Justices Consumer Protection Branch.
Besides maintaining the 2025 emissions reduction target of 15 percent for heavy trucks, the regulation also establishes new targets. The law called for a gradual reduction of the eco-innovation credits available to manufacturers and regular reports detailing progress toward these goals. The regulation proposes various objectives.
The manufacture and importation of single-use plastics will be banned in December 2022. Further, the Canadian Government “will also prohibit the export of [banned] plastics … by the end of 2025[.]” However, specific case exceptions will be included, including medically-necessary flexible straws.
Trade Representative announced certain modifications to the actions taken in the Section 301 investigation including a list of subheadings eligible for consideration of temporary exclusion under an exclusion process for certain machinery used in domestic manufacturing. The deadline for submitting exclusion requests is March 31, 2025.
Hyman, Phelps & McNamara PC, (HPM), which will mark its 45thAnniversary on March 17, 2025, is pleased to announce that it is increasing its directors, counsel, and associates as it starts the year. Richardson has been promoted to Director. Kalie is the quintessential HPM lawyer.
On March 18, 2025, Judge Ronnie Abrams dismissed the lawsuit with prejudice , penning an opinion that upholds Local Law 154 as a valid exercise of local authority beyond the purview of EPCAs preemption clause. In other words, EPCAs text and structure clearly intended to avoid a patchwork of conflicting and unpredictable regulations.
8] In his decision, Judge Mehta concluded that Google violated antitrust laws by striking exclusive agreements with device manufacturers such as Apple and Samsung. [9] 8] In his decision, Judge Mehta concluded that Google violated antitrust laws by striking exclusive agreements with device manufacturers such as Apple and Samsung. [9]
Koblitz Last December, Congress narrowly avoided a shutdown by significantly paring down the originally proposed 2025 Appropriations bill, slashing away hundreds of programs and laws. The authors suggested that the developers of such therapies would receive a priority review voucher that they can sell to manufacturers of blockbuster drugs.
Gucci-owner Kering group, for example, has set a target to reduce greenhouse gas emissions by 50 percent by 2025. Meanwhile, LVMH used its perfume manufacturing facilities to make free hand sanitizer for the healthcare system in France.
1) publish a list of selected drugs in accordance with section 1192; (2) enter into agreements with manufacturers of selected drugs with respect to such period, in accordance with section 1193; (3) negotiate and, if applicable, renegotiate maximum fair prices for such selected drugs, in accordance with section 1194; and. (4)
In 2025, that reduction in base credit will increase to 15 percent and in 2026, the base credit amount for direct pay claimants that cannot achieve the domestic content requirements will be reduced by 100 percent. If they can’t, they won’t be able to claim the ITC, even though it is notionally available until 2032.
MoCRA Requirements: FDA registration for cosmetics facilities Product listings for each cosmetic product Adverse event reporting Safety substantiation Compliance with Good Manufacturing Practices (GMPs) Fragrance allergen labeling MoCRA also gives the FDA new records access and mandatory recall authority.
Laboratories struggling to understand the myriad implications of being regulated as device “manufacturers” were hopeful that additional guidance would shed light on how to apply FDA’s existing medical device regulatory framework to their operations. 803), Reporting of Corrections and Removals (21 C.F.R. § 806) and Complaint Files (21 C.F.R.
MDR FDA discussed a few preliminary steps that it says laboratories should take prepare for submitting MDRs as medical device manufacturers. SCG : Modified version of another manufacturer’s FDA-authorized test within scope described in preamble to LDT Final Rule. issues with the design, manufacturing, and components of the device).
Under the new law, Part B will continue to pay for discarded amounts from single-dose containers, but the manufacturer must pay a rebate (called a “refund”) to Medicare for discarded amounts above a specified threshold. The manufacturer responsible for paying the refunds will be the company whose NDC is on the label.
Bureau of Industry and Security (BIS) BIS imposed a $180,000 mitigated penalty against Indium Corporation for 11 exports of electronics manufacturing components to Russia. Fruit juice manufacturing company and its former president plead guilty to food safety crimes. genetically modified corn exports violate the U.S.
For those reporting companies established or registered before January 1, 2024, the deadline for the initial BOI report is January 1, 2025. For more information about our services, please visit www.riggsdavie.com or contact our practice group by email at dealteam@riggsdavie.com.
Both Boohoo and Shein have garnered consumer pushback as a result of their labor exploitation, particularly given growing consumer awareness of – and demand for transparency when it comes to – the supply chain issues that are commonly tied to fast fashion, and other types of apparel manufacturing, as well. billion by the end of 2025.
What Food Manufacturers Should Do The rule is effective February 25, 2025, and the compliance date of the rule is February 25, 2028. In preparation for the compliance date, food manufacturers should review their products to ensure that any product that uses a healthy label meets the new criteria.
Recall that CMS will require manufacturers of selected drugs to negotiate a maximum fair price (“MFP”) with the agency according to the following timeline (the dates apply from applicable year 2027 onwards). N/A June 30 The manufacturer must accept the price or counteroffer—with a rationale. CMS may respond to the counteroffer.
The exception to this is for textile, wool, and fur products as processing or manufacturing occurring in the U.S. billion by 2025, and at a CAGR of 6.8% The similarity in the rules is that neither Customs nor the FTC requires that goods made partially or wholly in the U.S. must be disclosed. billion to $604.34 to nearly $465.7
1, 2024, and through May 31, 2025. Machinery exclusions – In response to a directive from the President to establish a process by which interested persons may request that machinery used in domestic manufacturing be excluded, USTR added 312 subheadings to be eligible for consideration for temporary exclusions.
Eligible Tax Credits : The tax credits for which a local government may elect to receive direct payment are as follows (numbers are references to the applicable Internal Revenue Code provisions): 30C (alternative fuel refueling property) : up to a 30% tax credit for cost of natural gas, propane, hydrogen, electricity, E85, or diesel fuel blend vehicle (..)
He highlighted the following key features of TAP: An Innovative Approach To provide proactive support and guidance to medical device manufacturers, FDA has introduced a new CDRH position known as the “TAP Advisor.” up to 125 total products enrolled through FY 2025). up to 60 total products enrolled through FY 2024).
The FCC proposes to extend these requirements to DMAs 101-210 by phasing in 10 DMAs per year starting on January 1, 2025, meaning that the bottom 10 DMAs would not be phased in until January 1, 2035. additional hours of audio description per calendar quarter between 6 a.m. and 11:59 p.m. local time.
.” The Fifth Circuit Court of Appeals has determined that a manufacturer may seek judicial review in that circuit even if it neither resides nor has its principal place of business there, so long as its petition is joined by a seller of its products, such as a gas station or convenience store, based in the circuit. Cunningham v.
The grants, made in July 2023, were offered on a formula basis – $3 million for states and $1 million for MSAs – and grantees are required to complete three deliverables: a Priority Climate Action Plan (PCAP) that was due earlier this year, a Comprehensive Climate Action Plan (CCAP) due June 2025, and a status report due June 2027.
Notable Dates and Timelines – Program opens, beginning of FY 2023; Expediting reviews fully implemented, by FY 2024; Webpage with detailed criteria for acceptance and participation, October 1, 2022; Interim assessment, end of FY 2025; Public workshop, end of Q2 FY 2026. Notable Dates and Timelines – New MAPP published, by Dec.
We organize all of the trending information in your field so you don't have to. Join 99,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content